New drug combo shows promise for tough sarcoma cases
NCT ID NCT03414229
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, epacadostat and pembrolizumab, in people with advanced sarcoma that has spread or cannot be removed by surgery. The goal is to see if the combo can shrink tumors. About 30 adults who have already tried at least one other cancer treatment will take part. The study is active but no longer recruiting new participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle childhood sarcoma?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?
- Can a Patient's own immune cells fight advanced sarcoma?
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a new protein drug shield kids with cancer from dangerous infections?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?